Injectable Testosterone Dosing for Postmenopausal Women with HSDD

Alternative Treatment Options

• The American College of Obstetricians and Gynecologists recommends considering FDA-approved alternatives, such as flibanserin or bremelanotide, for postmenopausal women with HSDD 1, 2
• The North American Menopause Society suggests that intravaginal DHEA (prasterone) may improve sexual function in women with concurrent dyspareunia, as supported by the Journal of the National Comprehensive Cancer Network 3
• The National Comprehensive Cancer Network recommends vaginal testosterone cream as a potential safer alternative to systemic administration for some patients, particularly cancer survivors 3